Soligenix Inc. Targets Key Milestones in Rare Disease Treatment Pipeline
Soligenix Inc. (NASDAQ: SNGX), a biopharmaceutical company specializing in rare diseases with unmet medical needs, has recently provided a shareholder update detailing its clinical and strategic milestones. The company’s President and CEO, Dr. Christopher J. Schaber, emphasized the importance of upcoming data readouts for its lead candidates, including Phase 3 FLASH 2 results for HyBryte(TM) […]